Skip to main content

Day: September 7, 2022

MGP Ingredients Announces Participation in the 5th Annual Wells Fargo Consumer Conference

ATCHISON, Kan., Sept. 07, 2022 (GLOBE NEWSWIRE) — MGP Ingredients, Inc. (Nasdaq:MGPI), a leading provider of distilled spirits, branded spirits, and food ingredient solutions, today announced that the Company is scheduled to participate in one-on-one investor meetings throughout the day, as well as a fireside chat at the Wells Fargo Consumer Conference, on Wednesday, September 21, 2022, at 1:40 p.m. ET (10:40 a.m. PT). David Colo, president and CEO, David Bratcher, COO, and Brandon Gall, CFO, will participate in the fireside chat. Links to both live sessions, as well as replays available for 30 days, will be accessible from the “Events & Presentations” section of MGP Ingredients investor relations website at https://ir.mgpingredients.com. About MGP Ingredients, Inc.MGP Ingredients, Inc. (Nasdaq: MGPI) is a leading producer...

Continue reading

Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 242,600 shares of common stock to 36 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. 242,600 stock options were granted and have exercise prices ranging from $6.25 to $12.44 per share. All stock options will vest over four years, with 1/4th of the underlying shares vesting on the one-year anniversary of the applicable vesting...

Continue reading

Descartes Announces Fiscal 2023 Second Quarter Financial Results

Record Revenues and Income from Operations WATERLOO, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) announced its financial results for its fiscal 2023 second quarter (Q2FY23). All financial results referenced are in United States (US) currency and, unless otherwise indicated, are determined in accordance with US Generally Accepted Accounting Principles (GAAP). “Descartes had a very successful quarter helping customers navigate the complexities of global supply chains and logistics,” said Edward J. Ryan, Descartes’ CEO. “Geopolitical events, energy supplies and costs, and economic uncertainty have combined to present novel challenges for supply chain participants to manage. Our Global Logistics Network (GLN) is designed to help these shippers, carriers and logistics services...

Continue reading

Celestica Releases its 2021 Sustainability Report

TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS) (TSX: CLS), a leader in design, manufacturing, hardware platform, and supply chain solutions for the world’s most innovative companies, today announced the release of its 2021 Sustainability Report. The report demonstrates Celestica’s commitment to fostering a company-wide culture of sustainability focused on supporting people, the planet and the communities in which it operates. Prepared in accordance with the GRI Standards: Core Option, Celestica’s 2021 Sustainability Report can be viewed at www.celestica.com/sustainability-report . “Every day at Celestica we hold ourselves accountable for building a sustainable future for the next generation,” said Robert Ellis, Senior Vice President, Sustainability, and Chief Legal Officer, Celestica. “In 2021, we implemented...

Continue reading

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer, will present a corporate overview, which will be available on demand, starting on Monday, September 12th at 7:00am (ET), and the Company will be available for one-on-one meetings. The webcast will be available online at investor.oncternal.com for up to 30 days. About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the...

Continue reading

ManTech Stockholders Approve Acquisition by Carlyle

Kevin M. Phillips, ManTech Chairman, Chief Executive Officer and President “We look forward to completing the transaction with Carlyle to deliver immediate and premium value to our stockholders, stronger outcomes for our customers and more opportunities for our employees.”HERNDON, Va., Sept. 07, 2022 (GLOBE NEWSWIRE) — ManTech International Corporation (Nasdaq: MANT) (“ManTech” or the “Company”), a leading provider of innovative technologies and solutions for mission-critical national security programs, today announced that its stockholders approved a proposal to adopt the merger agreement entered into between the Company and Carlyle (NASDAQ: CG) at a Special Meeting of Stockholders held on September 7, 2022. As previously announced, under the terms of the transaction, ManTech stockholders will receive $96.00 per share in cash. “We...

Continue reading

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitis Lead indication, atopic dermatitis, is a rapidly growing, significantly underserved market with large unmet need Checkpoint agonism is a promising emerging pathway for the treatment of atopic dermatitis, with preclinical and clinical validation data suggesting a durable biologic response DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitisWESTLAKE VILLAGE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,...

Continue reading

AMREP Reports First Quarter Fiscal 2023 Results

HAVERTOWN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $1,912,000, or $0.36 per diluted share, for its 2023 fiscal first quarter ended July 31, 2022 compared to net income of $1,637,000, or $0.22 per diluted share, for the same period of the prior year. Revenues were $11,232,000 for the first quarter of 2023 and $10,507,000 for the first quarter of 2022. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (www.amrepcorp.com/sec-filings/). AMREP Corporation, through its subsidiaries, is a major holder of land, leading developer of real estate and award-winning homebuilder in New Mexico.         FINANCIAL...

Continue reading

Wabash Introduces Acutherm Sub-Brand for Intelligent Thermal Management

LAFAYETTE, Ind., Sept. 07, 2022 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC), the visionary leader of connected solutions for the transportation, logistics and distribution industries, today introduced Wabash Acutherm™, a new portfolio of solutions designed for intelligent thermal management. Wabash Acutherm thermal solutions provide enhanced levels of thermal efficiency and management for both hot and cold applications. With superior thermal capability and structural integrity, temperature states can be maintained regardless of application or environmental conditions. “Wabash Acutherm is a testament of our commitment to meeting the demands of the cold chain market, as well as other areas of transportation where temperature control is critical to food safety and consumer health,” said President and Chief Executive Officer Brent Yeagy....

Continue reading

Kalera to Host Virtual Analyst and Investor Event on September 22

ORLANDO, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — Kalera Public Limited Company (Nasdaq: KAL, “Kalera” or the “Company”), a vertical farming company, today announced it will host a 90-minute Virtual Analyst and Investor Event on Thursday, September 22, 2022 at 1:00 p.m. Eastern Time. Analysts and investors will have the opportunity to hear from Kalera senior management on the compelling global market opportunity in Controlled Environment Agriculture (CEA), and specifically vertical farming; the company’s differentiated Consumer Packaged Goods (CPG) strategy; its priorities for profitable growth; an overview of operations and unit economics; an update on Kalera’s superior technology platform, and key financial metrics​. Kalera’s vision is to lead the world to sustainable nourishment and is on a mission to be the recognized leader...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.